Organization · Venture Capital
Brace Pharma Capital
Brace Pharma Capital is a strategic investment firm based in Atlanta, focused on innovative therapies for diseases with significant unmet medical needs. It was formed by EMS S/A and high-net-worth biotech investors.
Overview
What Brace Pharma Capital does
What Brace Pharma Capital is
Brace Pharma Capital is a strategic investment firm based in Atlanta, focused on innovative therapies for diseases with significant unmet medical needs. It was formed by EMS S/A and high-net-worth biotech investors.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2012
- Approximate age
- About 14 years
- Structured capabilities
- Funder
- Last reviewed
- May 1, 2026
Official channels
Find Brace Pharma Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Brace Pharma Capital as a funder
Investment thesis
Brace Pharma Capital invests in innovative therapies targeting diseases with significant unmet medical needs, focusing on life-changing treatments with the potential to reach market within defined regulatory timelines.
Focus narrative
The firm invests primarily in the biotechnology and pharmaceutical sectors, targeting innovative therapies that address significant unmet medical needs. Brace Pharma Capital is particularly interested in life-changing treatments that can demonstrate FDA-validated efficacy endpoints and have the potential for substantial market impact.
Value beyond capital
Brace Pharma Capital adds value to its portfolio companies by leveraging its expertise in clinical and regulatory affairs, providing strategic guidance, and facilitating connections within the biopharma ecosystem. The firm focuses on projects with strong management teams and aims to support the commercialization of innovative therapies.
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B · Series C · Growth Equity
- Regions
- North America · Global
Availability
- Currently deploying
- Not published
Portfolio and track record
- Recorded portfolio count
- 10
Portfolio context
Notable portfolio companies include: Avidity Biosciences (NASDAQ: RNA): Developing antibody-siRNA conjugates (ARCs™). AVROBIO (NASDAQ: AVRO): Developing lentiviral-based gene therapies. Precision Biosciences (NASDAQ: DTIL): Developing ARCUS genome editing for oncology and genetic disorders. Zymeworks (NYSE: ZYME): Developing protein therapeutics for cancer and autoimmune diseases. Antiva Biosciences: Focused on localized treatments for HPV-associated diseases. F2G: Developing therapeutics for life-threatening fungal diseases. Gliknik: Creating therapeutics for cancer and immune disorders. Navitor Pharmaceuticals: Developing selective mTORC1 modulators. ReViral: Developing antiviral drugs for RSV. Turnstone Biologics: Developing viral immunotherapies for cancer. Vero Biotech: Innovating inhaled nitric oxide products.
Common questions
What to know about Brace Pharma Capital
Upseed classifies Brace Pharma Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 1, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.